Your prediction
Pros and Cons of Merrimack Pharmaceuticals Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Merrimack Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 1.150% | 4.938% | 4.547% | -6.506% | 1.873% | 194.138% | -2.880% |
| Krystal Biotech | 1.290% | 8.522% | 17.592% | 14.742% | 32.194% | 183.380% | - |
| Evolus Inc | 0.880% | -1.724% | -5.785% | -51.695% | -45.714% | -12.977% | 91.019% |
Comments
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
